DNMT1 and myelodysplastic syndrome: DNA methyltransferases (DNMTs) are key enzymes that maintain DNA methylation.24 DNMT inhibitors can induce the re-expression of silenced tumor suppressors by decreasing DNA methylation levels.25 There are two FDA-approved DNMT inhibitors, 5-aza-2′-deoxycytidine (decitabine) and 5-aza-cytidine (azacitidine), which act as nucleoside analogs for incorporation into newly synthesized DNA strands.26 These two agents have been successfully used to treat myelodysplastic syndrome (MDS) and myeloid hematologic malignancies.